Free press releases distribution network?

Agency / Source: PharmaJet, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



PharmaJet and USAMRIID Collaborate on Smallpox Vaccine Combined with Needle-free Delivery Technology - Searching for more effective methods to deliver DNA vaccines, USAMRIID's experimental vaccine against smallpox will be evaluated in pre-clinical studies utilizing PharmaJet's needle-free injection technology
PharmaJet and USAMRIID Collaborate on Smallpox Vaccine Combined with Needle-free Delivery Technology

 

PRZOOM - /newswire/ - Golden, CO, United States, 2010/12/06 - Searching for more effective methods to deliver DNA vaccines, USAMRIID's experimental vaccine against smallpox will be evaluated in pre-clinical studies utilizing PharmaJet's needle-free injection technology.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

A Cooperative Research and Development Agreement (CRADA) has been signed between PharmaJet, Inc. and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to utilize the PharmaJet needle-free jet injection delivery technology in conjunction with USAMRIID’s candidate gene-based smallpox vaccine.

Patented under the name 4pox, the USAMRIID vaccine consists of a combination of genes that, when delivered together, provides protection from orthopoxviruses (e.g., vaccinia virus, monkeypox virus) in animal models. Under the guidance of USAMRIID’s Dr. Jay Hooper, immune responses to four different co-delivered immunogens will be evaluated using the PharmaJet needle-free system for intradermal delivery and compared with existing data produced with both PharmaJet and alternative devices.

“PharmaJet is very pleased to continue to work with USAMRIID,” said Linda McAllister, acting CEO for PharmaJet. “We are very excited about the potential for our needle-free, jet injection, intradermal technology to contribute to the efficacy of this important new class of DNA-based vaccines.”

The gene-based molecular vaccine field continually searches for safe, effective and practical delivery technologies, as well as adjuvant technologies. The 4pox gene-based vaccine has already been evaluated in preclinical models using skin and muscle electroporation and gene gun technology, among other means of delivery. The use of PharmaJet needle-free technology to deliver other DNA vaccines of military importance may be evaluated and added under addendums to this agreement.

About PharmaJet, Inc. and Needle-free Injections
PharmaJet’s needle-free technology (pharmajet.com) delivers vaccines to intramuscular, subcutaneous, and intradermal tissue depths. “Jet” injectors use pressure to create a fine stream of liquid that penetrates the skin, delivering doses of medications and vaccines while reducing the burden of hazardous waste management. The potential benefits of jet injectors include more consistent delivery, reduced vaccine wastage, elimination of the need to transport large volumes of sharps, and reduction of the risk of needle sticks and of the costs associated with sharps waste. For some vaccines, intradermal delivery has the potential to reduce the amount of vaccine required, in some cases by as much as 80%, leading to cost savings and expanded coverage for vaccines in limited supply.

Previous generations of jet injectors delivered billions of doses of vaccines over the last 60 years, but the multiple-use nozzles enabled cross-contamination between patients. Newer devices, such as the PharmaJet system, have been well received in the developed world, but are also extremely advantageous in the developing world because of their usability, affordability, and improved safety features (by design, PharmaJet’s “needle-free” syringe cannot be reused). Needle-free jet injection also has the potential to improve safety by eliminating needles from the process of administering vaccines, and eliminating sharps (used metal needles) from the environment.

About USAMRIID
USAMRIID (usamriid.army.mil), located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Department of Defense's Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute conducts basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. While USAMRIID’s primary mission is focused on the military, its research often has applications that benefit society as a whole. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

[The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.]

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: PharmaJet, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


PharmaJet and USAMRIID Collaborate on Smallpox Vaccine Combined with Needle-free Delivery Technology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Regina Todd - PharmaJet.com 
410-209-2389 todd[.]pharmajet.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any PharmaJet, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From PharmaJet, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com

Visit  Triggr & Bloom







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today